We describe a case of a patient with Graves' disease who failed to respond to carbimazole. Our patient remained thyrotoxic despite maximal carbimazole dosage. Our patient was switched to propylthiouracil which subsequently made the patient euthyroid. The patient was then definitively treated with radioiodine treatment. This case highlights the need to increase awareness of carbimazole-resistance as to prevent patients from being given escalating doses of carbimazole which increases the probability of adverse effects and extend their time in the hyperthyroid state.
INTRODUCTION
Thionamides which include Methimazole and carbimazole are the usual first line treatments in patients with Graves' disease. (1-3) Propylthiouracil (PTU), is usually used as a second-line treatment (exception being in the first trimester of pregnancy) due to its association with severe hepatotoxicity. (3) Most patients usually respond favourably to treatment with thionamides.
Our patient however did not respond to carbimazole and had carbimazole resistant thyrotoxicosis. (3)
CASE REPORT
Ms. VT is a 40-year-old female from Trinidad, West Indies. She is of Afro-Caribbean descent and presented with weight loss, palpitations and anxiety when examined by her family physician. Her thyroid test was as follows:
Free t3:13.9 (1.5-4.1 pg/ml) Free t4: 34.6 (0.35-6 ng/dl) TSH: 0.008 (0.4-4 µIU/ml)
The patient had a diffuse non-tender goitre which was confirmed by thyroid ultrasound with no nodules. She had a thyroid bruit and no signs of opthalmopathy. She was subsequently diagnosed with Grave's disease. She was started on Carbimazole 30 mg twice daily and propranolol 40mg three times daily and thyroid function tested 2 months later showed: Any patient with drug resistant Graves' disease should be questioned on compliance.
(6) We evaluated this by direct questioning of the patient and by supervised pill administration by her relative and was satisfied that our patient was in fact compliant with her medications.
Also, since the patient responded to PTU it is unlikely that the patient was non-compliant.
Our patient had no features suggestive of malabsorption on history or physical examinations.
Hence, patient was not further investigated for this. In this case, the patient was unable to afford private lab testing for drug levels or anti-drug antibodies. The perchlorate discharge test was not done due to unavailability in our country but has been used in the literature to differentiate resistance to carbimazole from non-compliance. This case features an important aspect of the treatment of Graves' disease. Our patient was resistant to treatment with carbimazole but responded favourably to switching the treatment to PTU. Physicians should be made aware of this possibility when treating hyperthyroid patients. Since if not aware, patients may be given unwarranted escalating doses of carbimazole. Our patient was given higher than the recommended dose of 60mg of carbimazole (3) by her family physician in a desperate attempt to control her hyperthyroidism.
The use of high doses of carbimazole consequentially is associated with increased probability of adverse effects and also lengthened patients' time in the hyperthyroid state.
